DAVID R. SNYDMAN, M.D.; JOHN A. BRYAN, M.D.; RICHARD E. DIXON, M.D.
SNYDMAN D., BRYAN J., DIXON R.; Prevention of Nosocomial Viral Hepatitis, Type B (Hepatitis B). Ann Intern Med. 1975;83:838-845. doi: 10.7326/0003-4819-83-6-838
Download citation file:
Published: Ann Intern Med. 1975;83(6):838-845.
Nosocomial viral hepatitis, type B, is assuming increasing importance in the United States. The keystone to an effective hepatitis control program is surveillance of patients and personnel, especially in high-risk areas, namely dialysis units, hematology-oncology units, and laboratories. Measures to control infection are outlined for specific areas of the hospital. Data currently available suggest that employees who have persisting hepatitis B surface antigen (HBsAg) need not be removed from their positions unless they have been proved to disseminate infection. Future investigations should include methods to study: [a] the mechanisms of non percutaneous spread of hepatitis B virus, [b] the role of the individual with persisting HBsAg in the dissemination of hepatitis B virus, [c] the efficacy of hepatitis B immune globulin in high-risk areas, and [d] the effectiveness of various chemical and physical procedures in use for inactivation of hepatitis B virus using animal model systems.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Viral Hepatitis, Liver Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only